http://www.zibb.com/all/theme/cq/Genentech+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 23 Nov 2009 00:00:00 GMTMon, 23 Nov 2009 00:00:00 GMT608831http://www.zibb.com/all/theme/cq/Genentech+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=185479087The biggest mergers and acquisitions witnessed so far in 2009 have been the Pfizer-Wyeth acquisition for $68 billion, Roche-Genentech $46.8 billion, Merck-Schering Plough $41B and Gilead Sciences-CV Therapeutics $1.4B. This accounted for a total of $157 billion dollars.http://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=185479087Genentech IncorporatedMon, 23 Nov 2009 00:00:00 GMThttp://www.biospace.com/news_story.aspx?StoryID=163403&full=1SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB - News) announced today that the U.S.http://www.biospace.com/news_story.aspx?StoryID=163403&full=1Genentech IncorporatedThu, 19 Nov 2009 12:00:00 GMThttp://www.drugstorenews.com/story.aspx?id=123511&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+DSNRssChannel+%28Drug+Store+News+RSS+channel%29The Food and Drug Administration has turned down a request by two biotech companies seeking approval for a drug as a treatment for chronic lymphocytic leukemia.http://www.drugstorenews.com/story.aspx?id=123511&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+DSNRssChannel+%28Drug+Store+News+RSS+channel%29Genentech IncorporatedThu, 19 Nov 2009 10:35:00 GMThttp://www.zibb.com/article/5681500/Genentech+and+Biogen+Idec+obtain+FDA+complete+response+for+leukemia+drugGenentech, a wholly-owned member of the Roche Group, and Biogen Idec have reported that the FDA issued a complete response on their applications for Rituxan plus fludarabine and cyclophosphamide for the treatment of people with previously untreated and previously treated chronic lymphocytichttp://www.zibb.com/article/5681500/Genentech+and+Biogen+Idec+obtain+FDA+complete+response+for+leukemia+drugGenentech IncorporatedThu, 19 Nov 2009 09:53:19 GMThttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=11061South San Francisco, Calif. and Cambridge, Mass. 18 November 2009 Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDAhttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=11061Genentech IncorporatedThu, 19 Nov 2009 01:00:00 GMThttp://abcnews.go.com/Business/wireStory?id=9119493Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion.http://abcnews.go.com/Business/wireStory?id=9119493Genentech IncorporatedWed, 18 Nov 2009 22:52:17 GMThttp://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/11/18/financial/f134813S46.DTL&feed=rss.businessGenentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration has asked for more information before considering approving Rituxan as a leukemia treatment. The drug is already approved as a treatment for rheumatoid arthritis and...http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2009/11/18/financial/f134813S46.DTL&feed=rss.businessGenentech IncorporatedWed, 18 Nov 2009 21:48:25 GMThttp://www.post-gazette.com/pg/09322/1014251-192.stm?cmpid=news.xmlHealth-care reform was always going to be difficult to achieve, but it may yet turn out to be the best that money can buy -- except that it may be special-interest money buying what it wants ...http://www.post-gazette.com/pg/09322/1014251-192.stm?cmpid=news.xmlGenentech IncorporatedWed, 18 Nov 2009 05:01:00 GMThttp://news.yahoo.com/s/nm/20091115/us_nm/us_genentech_lobbyistsLobbyists working for biotech company Genentech wrote statements for more than a dozen lawmakers in the official record of the House debate on the health care bill, The New York Times reported on Sunday, citing e-mails.http://news.yahoo.com/s/nm/20091115/us_nm/us_genentech_lobbyistsGenentech IncorporatedSun, 15 Nov 2009 19:15:59 GMThttp://seekingalpha.com/article/171337-surmodics-inc-q4-2009-earnings-call-transcript?source=feedSurModics, Inc. (SRDX)Q4 2009 Earnings CallNovember 4, 2009 5:00 PM<ahttp://seekingalpha.com/article/171337-surmodics-inc-q4-2009-earnings-call-transcript?source=feedGenentech IncorporatedThu, 05 Nov 2009 01:29:07 GMThttp://www.newsvine.com/_news/2009/10/28/3435062-medicare-reverses-billing-change-on-genentech-drugMedicare officials are backing off a policy that pushed many doctors to use a $2,000 injectable drug for a potentially blinding eye disorder, over a similar treatment that costs about $50.http://www.newsvine.com/_news/2009/10/28/3435062-medicare-reverses-billing-change-on-genentech-drugGenentech IncorporatedWed, 28 Oct 2009 17:25:26 GMThttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3496290&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3496290&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2279620359%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directoryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3496290&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3496290&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2279620359%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenentech IncorporatedThu, 22 Oct 2009 08:44:48 GMThttp://www.prnewswire.com/news-releases/ngm-biopharmaceuticals-appoints-dr-arthur-d-levinson-former-genentech-ceo-to-its-board-of-directors-65162272.htmlNGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors.http://www.prnewswire.com/news-releases/ngm-biopharmaceuticals-appoints-dr-arthur-d-levinson-former-genentech-ceo-to-its-board-of-directors-65162272.htmlGenentech IncorporatedWed, 21 Oct 2009 13:00:00 GMThttp://sanfrancisco.bizjournals.com/sanfrancisco/stories/2009/10/12/daily24.html?ana=from_rssRoche CEO Severin Schwan told the newspaper that compensation at Genentech, acquired by the Swiss company in March, is one of his top priorities in 2010.http://sanfrancisco.bizjournals.com/sanfrancisco/stories/2009/10/12/daily24.html?ana=from_rssGenentech IncorporatedTue, 13 Oct 2009 18:37:39 GMThttp://blog.searchenginewatch.com/091012-222044Arthur Levinson, former CEO of Genentech, has resigned Google's Board of Directors. Levinson had been on the board for five years. "Working with Eric, Larry, Sergey and the whole Google team has been a remarkable experience for me. I greatly admire what they've built and have no doubt that Googlehttp://blog.searchenginewatch.com/091012-222044Genentech IncorporatedTue, 13 Oct 2009 03:20:44 GMThttp://www.ft.com/cms/s/d2c9c4c8-b78e-11de-9812-00144feab49a,Authorised=false.html?_i_location=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2Fd2c9c4c8-b78e-11de-9812-00144feab49a.html%3Fftcamp%3Drss%26nclick_check%3D1&_i_referer=&ftcamp=rss&nclick_check=1The latest UK and international business, finance, economic and political news, comment and analysis from the Financial Times on FT.comhttp://www.ft.com/cms/s/d2c9c4c8-b78e-11de-9812-00144feab49a,Authorised=false.html?_i_location=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2Fd2c9c4c8-b78e-11de-9812-00144feab49a.html%3Fftcamp%3Drss%26nclick_check%3D1&_i_referer=&ftcamp=rss&nclick_check=1Genentech IncorporatedTue, 13 Oct 2009 02:00:00 GMThttp://venturebeat.com/2009/10/12/genentech-ceo-levinson-leaves-google-board-stays-with-apple/A dry press release from Google this morning announced the effective-immediately departure of Genentech chairman Arthur Levinson from Google's board ...http://venturebeat.com/2009/10/12/genentech-ceo-levinson-leaves-google-board-stays-with-apple/Genentech IncorporatedMon, 12 Oct 2009 16:08:38 GMThttp://www.thestandard.com/news/2009/10/12/genentech-ceo-levinson-leaves-google-board-stays-appleA dry press release from Google this morning announced the effective-immediately departure of Genentech chairman Arthur Levinson from Googles board of directors. Levinson remains on ...http://www.thestandard.com/news/2009/10/12/genentech-ceo-levinson-leaves-google-board-stays-appleGenentech IncorporatedMon, 12 Oct 2009 16:08:38 GMThttp://www.xconomy.com/seattle/2009/10/09/dendreon-recruits-genentech-ceo-former-lilly-manufacturing-chief-to-board/Seattle-based Dendreon recruited some serious industry experience in marketing and manufacturing today to its board of directors. The company has added Ianhttp://www.xconomy.com/seattle/2009/10/09/dendreon-recruits-genentech-ceo-former-lilly-manufacturing-chief-to-board/Genentech IncorporatedSat, 10 Oct 2009 00:37:46 GMThttp://www.pharmamanufacturing.com/industrynews/2009/174.html?CMP=ILC-rssBut can the head man in Basel keep R&D workers from following Genentech execs out the door?http://www.pharmamanufacturing.com/industrynews/2009/174.html?CMP=ILC-rssGenentech IncorporatedThu, 08 Oct 2009 07:00:58 GMThttp://www.pharmaceutical-business-review.com/news/amgen_presents_phase_3_trial_results_for_denosumab_090921Denosumab met all primary and secondary endpoints and demonstrated superior efficacyhttp://www.pharmaceutical-business-review.com/news/amgen_presents_phase_3_trial_results_for_denosumab_090921Genentech IncorporatedMon, 21 Sep 2009 17:19:47 GMThttp://www.genengnews.com/news/bnitem.aspx?name=63014409Biogen Idec and partners Genentech and Roche are discussing the filing of a new indication for Rituxan (rituximab) on the back of Phase III data suggesting that patients with follihttp://www.genengnews.com/news/bnitem.aspx?name=63014409Genentech IncorporatedThu, 17 Sep 2009 00:00:00 GMThttp://www.bizjournals.com/sanfrancisco/stories/2009/09/14/daily8.html?ana=from_rssBerkeley-based Xoma (NASDAQ: XOMA) said it will use $25 million from Genentech — a buyout of future royalties due from the Genentech eye drug Lucentis — plus $12.3 million from an equity financing deal, $6.1 million in restricted cash and $800,000 in unrestricted cash to repay the loan.http://www.bizjournals.com/sanfrancisco/stories/2009/09/14/daily8.html?ana=from_rssGenentech IncorporatedMon, 14 Sep 2009 18:02:11 GMThttp://biopharminternational.findpharma.com/biopharm/Online+Only/Top-10-Biologics-Sales-Top-41-billion/ArticleStandard/Article/detail/625068?ref=25Sales of the Top 10 biotech drugs exceeded $41.5 billion in 2008, according to a new report issued by BioWorld Today.http://biopharminternational.findpharma.com/biopharm/Online+Only/Top-10-Biologics-Sales-Top-41-billion/ArticleStandard/Article/detail/625068?ref=25Genentech IncorporatedWed, 09 Sep 2009 04:00:00 GMThttp://www.manufacturing.net/News-Roche-Replaces-Genentech-CEO-090809.aspxSwiss drug developer said Tuesday Ian Clark will replace Pascal Soriot as CEO of biotechnology unit Genentech in January.http://www.manufacturing.net/News-Roche-Replaces-Genentech-CEO-090809.aspxGenentech IncorporatedTue, 08 Sep 2009 18:00:00 GMT